MURRAY HILL, N.J.--(BUSINESS WIRE)--Jan. 24, 2003--C. R. Bard,
Inc. (NYSE - BCR) announced today that it has acquired the right to
purchase the assets of Genyx Medical, Inc., headquartered in Aliso
Genyx is a privately held medical device company that develops,
manufactures and markets Uryx(R), a proprietary injectable bulking
agent for the treatment of stress urinary incontinence. Terms of the
agreement were not disclosed.
A conservative estimate of 25 million Americans suffer from
urinary incontinence, a non-life threatening but often debilitating
condition. Some 85 percent of incontinence sufferers are female.
Minimally invasive bulking agent therapy is frequently used to treat
patients who are non-surgical candidates or who wish to delay surgical
treatment or who have failed surgical therapy.
William H. Longfield, chairman and chief executive officer,
commented, "The agreement to acquire Genyx affords Bard the
opportunity to further strengthen our leadership position in the
incontinence category, a significant growth area within urology. This
is one of many areas in which Bard intends to invest incremental
research and development funds as a means of driving new business and
building shareholder value."
Uryx is a proprietary liquid polymer injected into the area
surrounding the female urethra. Upon injection, the liquid transforms
into a spongy mass, providing support to the urinary sphincter,
reducing or eliminating the accidental loss of urine. Uryx is CE
marked. Genyx is in the final stages of a multi-center randomized
trial in the U.S. and anticipates filing a pre-market approval (PMA)
application with the FDA in the first half of 2003.
C. R. Bard, Inc., (www.crbard.com), headquartered in Murray Hill, New
Jersey, is a leading multinational developer, manufacturer and
marketer of health care products in the fields of vascular, urology,
oncology and surgical specialty products.
This press release contains forward-looking statements, the accuracy
of which is necessarily subject to risks and uncertainties. Please
refer to our September 30, 2002 Form 10-Q for a statement with regard
to forward-looking statements, including disclosure of additional
factors that could cause actual results to differ materially from
those expressed or implied.
||C. R. Bard, Inc.
||Todd C. Schermerhorn, 908/277-8139
||or (Media Relations)
||Holly P. Glass, 703/754-2848